ArticleBreast cancer research and treatment2009
DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study.
Article in Breast cancer research and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review.Breast care (Basel, Switzerland) · 2019Pooled it
- Pooled it
- A review of the use of tumour DNA methylation for breast cancer subtyping and prediction of outcomes.Clinical epigenetics · 2025Review
- DNA Methylation and Transcript Variant Analysis ofInternational journal of molecular sciences · 2025Article
- Epigenetic Silencing ofIndian journal of surgical oncology · 2023Article
- Active and secondhand smoke exposure throughout life and DNA methylation in breast tumors.Cancer causes & control : CCC · 2019Article
- Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors.Environmental research · 2018Article
- Sleep and Breast Cancer in the Western New York Exposures and Breast Cancer (WEB) Study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.BMC cancer · 2017Article
- Aberrant promoter methylation of cancer-related genes in human breast cancer.Oncology letters · 2016Article
- DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.Epigenetics · 2016Article
- Methylated circulating tumor DNA in blood: power in cancer prognosis and response.Endocrine-related cancer · 2016Review
- Associations of intakes of magnesium and calcium and survival among women with breast cancer: results from Western New York Exposures and Breast Cancer (WEB) Study.American journal of cancer research · 2016Article
- Adiposity is associated with p53 gene mutations in breast cancer.Breast cancer research and treatment · 2015Article
- Regulators associated with clinical outcomes revealed by DNA methylation data in breast cancer.PLoS computational biology · 2015Article
- Association of prediagnostic physical activity with survival following breast cancer diagnosis: influence of TP53 mutation status.Cancer causes & control : CCC · 2013Article
- Exposures in early life: associations with DNA promoter methylation in breast tumors.Journal of developmental origins of health and disease · 2013Article
- Alcohol consumption in relation to aberrant DNA methylation in breast tumors.Alcohol (Fayetteville, N.Y.) · 2011Article
- Body mass and DNA promoter methylation in breast tumors in the Western New York Exposures and Breast Cancer Study.The American journal of clinical nutrition · 2011Article
- FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors.International journal of cancer · 2011Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
Abstract
Aberrant DNA hypermethylation of gene promoter regions has been increasingly recognized as a common molecular alteration in carcinogenesis. We evaluated the association between major clinicopathological features and hypermethylation of genes in tumors among 803 incidence breast cancer cases from a large population-based case-control study conducted in Western New York State. DNA samples were isolated from archive paraffin embedded tumor tissue and were analyzed for hypermethylation status of the E-cadherin, p16, and RAR-beta(2) genes using real time methylation-specific polymerase chain reaction. The frequencies of hypermethylation were 20.0% for E-cadherin, 25.9% for p16, and 27.5% for RAR-beta(2) genes. For postmenopausal women, hypermethylation of E-cadherin tended to be more likely in progesterone receptor (PR) negative than in PR-positive tumors (odds ratio (OR), 1.41; 95% confidence interval (CI), 0.91-2.18). Hypermethylation of p16 tended to be more frequent among estrogen receptor (ER) negative cases than ER-positive cases (OR, 1.51; 95% CI, 1.01-2.32). Hypermethylation of RAR-beta(2) gene was inversely associated with histological and nuclear grade of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.